Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines

Proteomics

Volumn 10, Issue 21, 2010, Pages 3789-3799

  Dai, Zhiqin ^a   Yin, Jie ^a   He, Haojie ^a   Li, Wenrui ^b   Hou, Chunmei ^c   Qian, Xiaohong ^b   Mao, Ning ^c   Pan, Lingya ^a,d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Beijing Proteome Research Center   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d JIANGSU CANCER HOSPITAL   (China)

Author keywords

Cell biology; DIGE; Drug resistance; Mitochondria; Ovarian cancer; TOF MASS

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE ALPHA; CARBOPLATIN; CISPLATIN; MITOCHONDRIAL PROTEIN; PEROXIREDOXIN 3; PROTEIN ETF; PROTEIN PHB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ELECTRON TRANSPORT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RESPIRATORY CHAIN; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PEROXIREDOXINS; PROTEOMICS; REPRESSOR PROTEINS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78049409468     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200900685     Document Type: Article

References (49)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y. et al., Cancer statistics 2008. CA Cancer J. Clin. 2008, 58, 71-96.
2. Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B., Pizer, E. S. et al., Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3, 377-386.
3. Morin, P. J., Drug resistance and the microenvironment: nature and nurture. Drug Resist. Updat. 2003, 6, 169-172.
4. van Hensbergen, Y., Broxterman, H. J., Rana, S., van Diest, P. J. et al., Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin. Cancer Res. 2004, 10, 1180-1191.
5. Coukos, G., Rubin, S. C., Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet. Gynecol. 1998, 91, 783-792.
6. Rabik, C. A., Dolan, M. E., Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9-23.
7. Gutterman, D. D., Mitochondria and reactive oxygen species: an evolution in function. Circ. Res. 2005, 97, 302-304.
8. Wang, X., The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15, 2922-2933.
9. Gimenez-Bonafe, P., Tortosa, A., Perez-Tomas, R., Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 2009, 9, 320-340.
10. Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G. et al., Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 2006, 12, 5817-5825.
11. Custodio, J. B., Cardoso, C. M., Santos, M. S., Almeida, L. M. et al., Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology 2009, 259, 18-24.
12. Saitou, M., Isonishi, S., Hamada, T., Kiyokawa, T. et al., Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer. Oncol. Rep. 2009, 21, 199-204.
13. Liang, X. J., Finkel, T., Shen, D. W., Yin, J. J. et al., SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res. 2008, 6, 1499-1506.
14. Andrews, P. A., Albright, K. D., Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992, 52, 1895-1901.
15. Yan, X. D., Zhang, M. W., Pan, L. Y., Objective to explore the different mechanisms of to cisplatin (CDDP) resistance in human epithelial ovarian cancer cell lines by two different methods. Basic Clin. Med. 2006, 26, 739-744.
16. Li, L., Luan, Y., Wang, G., Tang, B. et al., Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int. J. Mol. Med. 2004, 14, 257-264.
17. Schramke, M. L., Orlowski, M., Mitochondrial genome of the dimorphic zygomycete Mucor racemosus. Curr. Genet. 1993, 24, 337-343.
18. Schneider, A., Charriere, F., Pusnik, M., Horn, E. K., Isolation of mitochondria from procyclic Trypanosoma brucei. Methods Mol. Biol. 2007, 372, 67-80.
19. Mokranjac, D., Neupert, W., Energetics of protein translocation into mitochondria. Biochim. Biophys. Acta. 2008, 1777, 758-762.
20. Graham, J. M., Ford, T., Rickwood, D., Isolation of the major subcellular organelles from mouse liver using Nycodena gradients without the use of an ultracentrifuge. Anal. Biochem. 1990, 187, 318-323.
21. Toda, T., Takeya, K., Koike, M., Mori, R., Electron microscopy of ultrathin sections of Myco-bacterium. I. Fine structure of the cells grown in vitro and in vivo. Proc. Jpn. Acad. 1960, 36, 372-375.
22. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
23. García-Ramírez, M., Canals, F., Hernández, C., Colomé, N. et al., Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007, 50, 1294-1303.
24. Kurtz, A., Lueth, M., Kluwe, L., Zhang, T. et al., Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol. Cancer Res. 2004, 2, 433-441.
25. Ernst, J. D., Hoye, E., Blackwood, R. A., Jaye, D., Purification and characterization of an abundant cytosolic protein from human neutrophils that promotes Ca2(+)-dependent aggregation of isolated specific granules. J. Clin. Invest. 1990, 85, 1065-1071.
26. Swenerton, K., Muss, H. B., Robinson, E. G. (Eds.), Salvage chemotherapy for refractory disease in Ovarian Cancer Controversies on Management, Churchill Livingstone, New York 1998, pp. 169-194.
27. Di Michele, M., Della Corte, A., Cicchillitti, L., Del Boccio, P. et al., A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. BBA-Proteins Proteomics 2009, 1794, 225-236.
28. Karp, N. A., Spencer, M., Lindsay, H., O'Dell, K. et al., Impact of replicate types on proteomic expression analysis. J. Proteome Res. 2005, 4, 1867-1871.
29. Cavalli, L. R., Liang, B. C., Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved? Mutat. Res. 1998, 398, 19-26.
30. Kagan, J., Srivastava, S., Mitochondria as a target for early detection and diagnosis of cancer. Crit. Rev. Clin. Lab. Sci. 2005, 42, 453-472.
31. Taylor, S. W., Fahy, E., Zhang, B., Glenn, G. M. et al., Characterization of the human heart mitochondrial proteome. Nat. Biotechnol. 2003, 21, 281-286.
32. Lang, B. F., Gray, M. W., Burger, G., Mitochondrial genome evolution and the origin of eukaryotes. Annu. Rev. Genet. 1999, 33, 351-397.
33. Jiang, X. S., Zhou, H., Zhang, L., A high-throughput approach for subcellular proteome: identification of rat liver proteins using subcellular fractionation coupled with two-dimensional liquid chromatography tandem mass spectrometry and bioinformatic analysis. Mol. Cell. Proteomics 2004, 3, 441-455.
34. Jiang, X. S., Dai, J., Sheng, Q. H., A comparative proteomic strategy for subcellular proteome research. Mol. Cell. Proteomics 2004, 4, 12-34.
35. Tay, V. K. S., Wang, A. S., Leow, K. Y., Ong, M. M. K., Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic. Biol. Med. 2005, 39, 949-959.
36. +/- mice, an animal model of discreet mitochondrial oxidative stress. Proteomics 2008, 8, 555-568.
37. Stults, J. T., Arnott, D., Proteomics. Methods Enzymol. 2005, 402, 245-289.
38. Govorun, V. M., Archakov, A. I., Proteomic technologies in modern biomedical science. Biochemistry (Moscow) 2002, 67, 1109-1123.
39. Pandey, A., Mann, M., Proteomics to study genes and genomes. Nature 2000, 405, 837-846.
40. James, P., Proteome Research: Mass Spectrometry, Springer, Berlin 2001.
41. Unlü, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
42. Yan, X. D., Pan, L. Y., Yuan, Y., Lang, J. H. et al., Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 2007, 6, 772-780.
43. Merkwirth, C., Langer, T., Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim. Biophys. Acta 2009, 1793, 27-32.
44. Czarnecka, A. M., Campanella, C., Zummo, G., Cappello, F., Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. Cancer Bio. Ther. 2006, 5, 714-720.
45. Fusaro, G., Wang, S., Chellappan, S., Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene 2002, 21, 4539-4548.
46. Gregory-Bass, R. C., Olatinwo, M., Xu, W. et al., Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int. J. Cancer 2008, 122, 1923-1930.
47. Artal-Sanz, M., Tavernarakis, N., Prohibitin and mitochondrial biology. Trends Endocrinol. Metab. 2009, 20, 394-401
48. Yan, X. D., Li, M., Yuan, Y., Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations. Oncol. Rep. 2007, 17, 1163-1169.
49. Black, D., Solomon, E., The search for the familial breast/ovarian cancer gene. Trends Genet. 1993, 9, 22-26.